Lifestyle

Are psychedelics going mainstream? 28% of Americans have tried at least one psychedelic drug, new poll reveals

Published on August 11, 2022
Bright red psychedelic mushrooms. The dabbing technique near the edges gives a soft focus effect due to the altered surface roughness of the paper.
(AdobeStock)

This article was written by Nina Zdinjak and originally published on Benzinga.

As people are becoming more open to experimenting with alternative treatments for various health issues, or simply for wellness purposes, both cannabis and psychedelics are coming into play. While it has been confirmed that cannabis is the world’s most consumed substance, with around 209 million people using it in 2020, psychedelics are another story. At least for now.

Nevertheless, things seem to be changing. 

According to a new poll by YouGov, some 28% of Americans have tried at least one psychedelic drug. The poll, which questions 1,000 adults between 22-25, revealed that the most used psychedelic substance is LSD and that 14% of participants confirmed trying it, followed closely by psilocybin with 13%.

Related
Types of psychedelics

Psychedelics poll highlights 

  • 9% of participants have tried MDMA, 6% ketamine, 6% DMT, and 5% salvia;
  • 51% of those self-defining as very liberal have tried at least one psychedelic substance;
  • 42% of those with a family income of at least $100,000 have tried at least one psychedelic substance; 
  • 42% of participants with a postgraduate degree confirm they tried one psychedelic drug;
  • Out of those who have tried one, 39% belonged to the 30-44 age group, and 37% were Americans living in the Western part of the U.S.;
  • Among those questioned, the following groups showed the lowest propensity for trying psychedelic substances: Black Americans – 14% have tried; seniors (aged 65 and older) – 14%; Protestants – 19%; people living in rural areas – 19%; conservative people – 21%.
Related
How to dose psychedelic mushrooms

Stances on decriminalization 

While progress on psychedelic decriminalization and research has been noticed over the last couple of years, most Americans are still against it, and many don’t even know why the poll reveals.

  • By 44% to 27%, Americans oppose decriminalizing psilocybin (mushrooms);
  • By 53% to 20%, Americans oppose decriminalizing LSD (acid);
  • By 53% to 19%, Americans oppose decriminalizing MDMA (ecstasy);

Those who have tried one of these three drugs are more inclined toward backing their decriminalization. 

  • 68% of people who have tried psilocybin say it should be legal;
  • 48% of people who’ve tried MDMA say it should be legal;
  • 43% of people who have tried LSD say it should be legal;

House Reps. Alexandria Ocasio-Cortez (D-N.Y.) and Dan Crenshaw (R-Texas) recently filed separate bills toward further advancing research on psychedelic-assisted post-traumatic stress disorder (PTSD) treatments for veterans. Based on the poll, some 54% of Americans support that type of research, while 18% are against it.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
Benzinga
Benzinga
Benzinga's mission is to connect the world with news, data, and education that makes the path to financial prosperity easier for everyone, every day.
View Benzinga's articles
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play




* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2024 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.